A substance of biological origin that is soluble in nonpolar solvents
POPULARITY
Categories
99 episodes with lipids
28 episodes with lipids
15 episodes with lipids
9 episodes with lipids
11 episodes with lipids
7 episodes with lipids
13 episodes with lipids
7 episodes with lipids
6 episodes with lipids
9 episodes with lipids
7 episodes with lipids
7 episodes with lipids
7 episodes with lipids
4 episodes with lipids
31 episodes with lipids
8 episodes with lipids
6 episodes with lipids
8 episodes with lipids
5 episodes with lipids
4 episodes with lipids
6 episodes with lipids
7 episodes with lipids
5 episodes with lipids
4 episodes with lipids
3 episodes with lipids
4 episodes with lipids
6 episodes with lipids
4 episodes with lipids
7 episodes with lipids
4 episodes with lipids
6 episodes with lipids
3 episodes with lipids
3 episodes with lipids
6 episodes with lipids
6 episodes with lipids
4 episodes with lipids
6 episodes with lipids
3 episodes with lipids
5 episodes with lipids
8 episodes with lipids
5 episodes with lipids
3 episodes with lipids
5 episodes with lipids
8 episodes with lipids
8 episodes with lipids
10 episodes with lipids
3 episodes with lipids
3 episodes with lipids
5 episodes with lipids
6 episodes with lipids
3 episodes with lipids
2 episodes with lipids
5 episodes with lipids
3 episodes with lipids
Today, I'm honored to reconnect with fan favorite, Dr. Tom Dayspring. Dr. Dayspring is a fellow of both the American College of Physicians and the National Lipid Association, and is certified in internal medicine and clinical lipidology with extensive experience in perimenopause and menopause management. He has been a frequent contributor and educator at Everyday Wellness. In this episode, we discuss labs that help to monitor changes in insulin resistance (specifically the LPIR score), the clinical practice limitations Dr. Dayspring believes stem from a lack of humility, and aspects of women's medical histories that may indicate greater heart disease risk. We examine statin therapy and other treatment modalities, premature menopause and cardiovascular disease risks, Lp(a) as the primary inherited risk factor for heart disease, and current guidelines, treatment goals, and recommendations. Dr. Dayspring also shares his thoughts on estrogen patch shortages and oral estradiol therapy challenges with elevated triglycerides. As always, this is an invaluable conversation with Dr. Tom Dayspring. Stay tuned for an upcoming podcast with Dr. Dayspring, where we'll focus on lipids and brain health. IN THIS EPISODE, YOU WILL LEARN: Lipoprotein changes and how they can reveal insulin resistance before fasting insulin or glucose begin to rise Why someone can be insulin resistant while showing normal triglyceride levels The importance of looking at a woman's broader medical history to find potential cardiovascular risk signals Why premature menopause and premature ovarian failure should be taken seriously as cardiovascular and long-term health risk factors How Lp(a) is the most inherited risk factor for atherosclerotic heart disease across the population Why women may benefit from repeat Lp(a) testing around the menopausal transition What clinicians may address when Lp(a) is elevated, including other modifiable cardiovascular risk factors Oral estrogen may have a beneficial effect on Lp(a). How epidemiological evidence has linked endometriosis with heart disease Why Dr. Dayspring recommends checking ApoB when triglycerides are elevated Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow. Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Connect with Dr. Tom Dayspring On X (@DrLipid) LinkedIn
What if mitochondria aren't the beginning of the cellular energy story? Dr. Jill welcomes back Bob Miller to explore the cell membrane as the body's power grid and how cardiolipin, ATP, oxidative stress, genetics, and membrane damage may influence energy, inflammation, neurological function, and complex chronic illness.
This episode focuses on missed opportunities to intensify lipid-lowering therapy, highlighting gaps where treatment escalation could improve lipid management and cardiovascular risk reduction. The discussion centers on recognizing when lipid control is inadequate and on the role of the clinical pharmacist in optimizing medications, including PCSK9i, statins, and emerging therapies, to better align with patient risk and treatment goals. Read the full article at: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.70209
Listen in as our expert panel breaks down what clinicians need to know about the 2026 dyslipidemia guidelines, such as the role of lipoprotein a, apolipoprotein B, and coronary artery calcium scoring. Plus, you'll walk away with practical takeaways to optimize lipid management including when to add non-statin therapies like PCSK9 inhibitors and ezetimibe for your patients.Special guests:Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLAExecutive Director, Ambulatory Pharmacy ServicesGrady Health SystemJoel C. Marrs, PharmD, MPH, BCACP, BCCP, BCPS, CLS, FAHA, FASHP, FCCP, FNLACardiology Ambulatory Clinical PharmacistCheyenne Regional Medical Group Heart & Vascular InstituteAdjoint Associate ProfessorUniversity of Colorado School of MedicineYou'll also hear practical advice from panelists on TRC's Editorial Advisory Board:Stephen Carek, MD, CAQSM, DipABLMClinical Associate Professor of Family MedicinePrisma Health/USC-SOMG Family Medicine Residency ProgramUSC School of Medicine GreenvilleAndrea Darby-Stewart, MDAssociate Director, Honor Health Family Medicine Residency ProgramClinical Professor of Family, Community & Occupational MedicineThe University of Arizona College of Medicine - PhoenixCraig D. Williams, PharmD, FNLA, BCPSClinical Professor of Pharmacy PracticeOregon Health and Science UniversityFor the purposes of disclosure, Dr. Cheeley reports relevant financial relationships with [lipids] Novartis, Regeneron (honorarium). The other speakers have nothing to disclose. All relevant financial relationships have been mitigated.This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in July 2026.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NPY865. CME credit will be available until August 24, 2027.Taking Initiative to Optimize Lipid-Lowering Therapy in High-Risk Patients With ASCVD: A Call to Action for CardiologistsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NPY865. CME credit will be available until August 24, 2027.Taking Initiative to Optimize Lipid-Lowering Therapy in High-Risk Patients With ASCVD: A Call to Action for CardiologistsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NPY865. CME credit will be available until August 24, 2027.Taking Initiative to Optimize Lipid-Lowering Therapy in High-Risk Patients With ASCVD: A Call to Action for CardiologistsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/NPY865. CME credit will be available until August 24, 2027.Taking Initiative to Optimize Lipid-Lowering Therapy in High-Risk Patients With ASCVD: A Call to Action for CardiologistsThe University of Cincinnati is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The University of Cincinnati and PVI, PeerView Institute for Medical Education, are both accredited by the ACCME to provide continuing medical education for physicians and have collaborated to design and execute this activity. For accreditation purposes, the University of Cincinnati is responsible for certification and documentation of attendance for this activity.SupportThis activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.Disclosure information is available at the beginning of the video presentation.
Pediatric Insights: Advances and Innovations with Children’s Health
Should every child be screened for high cholesterol, and what happens afterward? Sadia Malik, M.D., Pediatric Cardiologist at Children's Health and Associate Professor at UT Southwestern, describes the LEAD Initiative and why guidelines recommend a universal lipid check around ages 9–11. Learn more.
Podcast Host and Interviewee: Host: Dr. Daniel Zamler Interviewee: Dr. Jian Hu Podcast Description: Dr. Daniel Zamler interviews Dr. Jian Hu on the multifaceted role that lipids play in the glioma microenvironment, with discussion on lipids in tumor cells, myeloid cells, and neurons.
Welcome to this week's Midlife Minute episode! Statistically, one in three women will die of heart disease. So, today, we're answering some of the many questions I received about lipids and heart health. Although I've done other lipid-focused Midlife Minutes before, this episode is yet another dedicated to Dr. Tom Dayspring, as I've received such a vast number of questions on this particular topic. IN THIS EPISODE, YOU WILL LEARN: Why understanding your ApoB and Lp(a) is an essential part of assessing your cardiovascular risk Why treatments for lipid abnormalities should be individualized to fit each specific abnormality Essential lifestyle measures for supporting overall cardiovascular health How CAC scoring, CT coronary angiography, and Clearly AI-assisted imaging differ, what each test measures, and their limitations How cardiovascular disease can sometimes present differently in women Why are premature atrial contractions and premature ventricular contractions often benign when the heart is structurally normal? How the roles of statins, ezetimibe, PCSK9 inhibitors, GLP-1 medications, and emerging RNA therapies differ, and why they should not be considered interchangeable How declining estrogen impacts cardiovascular health Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow. Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line
Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up into an endosome, and the payload has to escape that compartment before it is degraded. Endosomal escape is where a large share of the dose is lost, and it is why delivery, not the genetic construct, is usually the thing that limits the therapy. Lipid nanoparticles carry a second constraint, since they tend to accumulate in the liver, which narrows the diseases they can reach. What if the particle never entered that way at all?Jitendra Kumar, Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, works on a platform that fuses directly with the cell membrane and releases its cargo straight into the cytosol. He came to nanoparticle design the long way, through fifteen years of structural biology on the prion protein in Frankfurt and Edmonton, which is why he thinks about particle size, packaging and diffusion the way he does.Key topics discussed:Jitendra's career background in structural biology and journey to Entos Pharmaceuticals (03:18)The scientific motivation and challenges of working with prion proteins and breaking down complex diseases (04:55)Genetic medicine approaches: gain-of-function vs. loss-of-function, and the role of siRNA, ASOs, and gene delivery (06:27)The FAST protein platform: origins, function, and advantages for drug delivery (07:56)Manufacturing differences compared to LNPs, including the introduction of recombinant membrane protein production and related CMC complexity (09:55)Scale-up and production challenges for membrane proteins, and strategies for clinical supply (11:21)Clinical development progress: Phase 1/2 studies with the platform, especially for COVID vaccine delivery (12:23)Focus areas for the technology, including selective lung delivery and leptin therapy for lipodystrophy (13:12)Lessons for small biotech companies in phase 1/2 manufacturing strategy, technology transfer, and the value of an experienced network (14:31)Balancing process robustness with speed in new biotech ventures (16:02)The importance of identifying “pause steps” and must-have vs. nice-to-have features in early manufacturing processes (17:15)Smart insight: Jitendra's takeaway for startups: for early phases, find a partner who genuinely understands your tech and can move at your pace rather than defaulting to a big CDMO, treat your network as infrastructure, and build the ability to run production in-house. The one thing that's never up for negotiation is process robustness. The real question isn't robustness vs. speed, but how many checkpoints and safe pause points you build in so you can have both.If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper:Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed YoussefEpisodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark MelvilleConnect with Jitendra Kumar:LinkedIn: www.linkedin.com/in/jkumar2Email: jitendra.kumar@entospharma.comWebsite: www.entospharma.comFree 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it hereSupport the show
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-499 Overview: Stay in the know with this breakdown of the latest American College of Cardiology (ACC)/American Heart Association (AHA) recommendations for lipid testing and management. New approaches to evaluating hyperlipidemia, as well as limitations of the updated guidelines, are discussed to provide you with practical strategies for tailoring treatment decisions to individual patient risk. Episode resource links: Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-499 Overview: Stay in the know with this breakdown of the latest American College of Cardiology (ACC)/American Heart Association (AHA) recommendations for lipid testing and management. New approaches to evaluating hyperlipidemia, as well as limitations of the updated guidelines, are discussed to provide you with practical strategies for tailoring treatment decisions to individual patient risk. Episode resource links: Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Send us Fan MailThe biology of endogenous cannabinoids & history of cannabinoid-based therapeuticsTOPICS DISCUSSED:Anandamide vs 2-AG: The two major endocannabinoids with a shared arachidonic acid backbone but distinct head groups biological roles.On-demand production: Calcium-dependent enzymes release cannabinoids from membranes in response to neuronal activity patterns.Trafficking: Fatty acid binding proteins and extracellular microvesicles traffic endocannabinoids within and between cells.Adolescent THC: Global receptor activation during circuit wiring may contribute to cannabis use disorder and psychosis vulnerability in susceptible individuals.Enzyme inhibitors: Early FAAH clinical trial halted by off-target toxicity; MAGL inhibitors advancing in phase 2 for anxiety and addiction.Peripheral CB1: Liver receptors regulate metabolism; restricted antagonists aim to reduce weight without central psychiatric risks of the weight loss drug rimonabant.ABOUT THE GUEST: Nephi Stella, PhD is a professor at the University of Washington School of Medicine. He has studied endocannabinoid signaling for more than 25 years, focusing on therapeutic strategies that separate beneficial effects from side effects of cannabinoid-system modulation.Support the showSupport my work:Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.For all the ways you can support my efforts.
Commentary by Dr. Kevin Tang.
ReferencesLipids.1982. 17, pages 551–557 Biochimica et Biophysica Acta (BBA) 1977- Lipids and Lipid Metabolism 486(3): 451-461Plant Physiol 1986 Oct;82(2):448-53Lipids 41, 739–747 (2006)Guerra, DJ.2026. Unpublished Lectures.Ungar et al. 1999. Ashokan Farewellhttps://music.youtube.com/watch?v=r9TcXmBNbtM&si=8YXv3K_RXgggy9wPTaylor, J. 1970. Sweet Baby Jameshttps://open.spotify.com/track/17PXXzOygMyXXUNLngVN5u?si=5544e583f0044dc6Hunter/Garcia.1970. Ripple. Grateful Deadhttps://open.spotify.com/track/4aQ8mFkZU6dmHaZOOKdscc?si=f0f9303fe3df49b8Tchaikovsky, PI. 1878. Violin Concerto in D Major OP. 35.https://music.youtube.com/watch?v=2CtUNOW6Xtk&si=U5dPlmzn9UNSwzrW
Nurse practitioner and cardiology expert Colleen Walsh-Irwin returns to NP Pulse to give us all an overview of the latest guidelines for dyslipidemia. Walsh-Irwin walks us through what the new guidelines recommend, and details how NPs can work with patients to prevent cardiovascular disease and improve LDL-C scores. This podcast made possible by Amgen.
References Sci. Signal.2019;12:eaau2293Mol Metab. 2020 Feb 3;34:136–145 J Neurochem. 2009 Jun 22;110(5):1388–1399.Front Physiol. 2023 May 4;14:1167873.Front Biosci . 2024 Apr 11;29(4):148Guerra, DJ.2026. Unpublished LecturesMozart WA . 1787. Don Giovanni Overture K 527.https://open.spotify.com/track/11eD0BMMlDZQnQd4XaNzpS?si=d558cb397118440a
Welcome back to the Jack Westin MCAT Podcast with Mike and Molly! Last episode was DNA techniques. This episode we finally give some love to the most underappreciated of the four macromolecules: lipids.Lipids do not get the same attention as proteins or carbohydrates on the MCAT, but Mike makes a strong argument in this episode that lipids are actually the macromolecule that defines the cell. Without them, there is no inside versus outside. Without them, nothing gets concentrated, nothing gets protected, and nothing gets separated from the environment.This episode covers everything from the chemistry of fatty acids to why fish in cold water have healthier fats than you do.Get started with our resources!
Why is gene therapy still so difficult to manufacture at scale after decades of progress?Phillip Ramsey, Chief Technical Officer at Sangamo Therapeutics, joins BioTalk Unzipped for a candid conversation about one of the central challenges facing advanced therapies: turning extraordinary science into reproducible, scalable medicines.Thank You to Our SponsorsLeucentra - https://leucentra.com/Inspired by Science. Empowered by IT. Leucentra provides specialized IT consulting and services for life sciences and healthcare, helping organizations use technology more effectively to support innovation.TruTechnologies - https://trutechnologies.ai/Clinical Trial Execution, Live. TruTechnologies provides live clinical trial execution technology that gives sponsors greater visibility into protocol activities, samples, and study data as they happen.About This EpisodeRecorded onsite at the AAPS National Biotechnology Conference in Boston, Phillip explains why gene therapy manufacturing has not yet reached the maturity of monoclonal antibody production.As technologies have evolved across retroviral vectors, lentiviral vectors, adenovirus, AAV, lipid nanoparticles, and other advanced modalities, development teams have repeatedly been required to rethink fundamental manufacturing and analytical questions.Phillip discusses why analytics are critical, why experience across multiple manufacturing lots and products matters, and why there simply is no shortcut to developing the scientific knowledge necessary to manufacture advanced therapies reliably.He also reflects on the uncertainty of biotechnology.Early in his career, Phillip was walking down a hallway when his CFO asked if he had cashed his paycheck.When he said no, she told him not to.It's a remarkable story that captures something rarely discussed about biotechnology: behind transformative science are people willing to operate through considerable uncertainty while trying to build something that has never existed before.Gregory and Phillip Discuss• Viral vector manufacturing and scale-up• Why analytics are essential to gene therapy development• AAV manufacturing challenges• Lentiviral vectors and other evolving delivery technologies• Lipid nanoparticles and changes in advanced therapy manufacturing• Why gene therapy cannot simply adopt the established monoclonal antibody manufacturing playbook• Building process knowledge across lots and products• Career resilience in biotechnology• Progress across AAV, CAR-T, and other advanced therapies• Gene therapy affordability• The importance of therapeutic durability• Outcomes-based payment models for advanced therapiesPhillip's message for scientists and industry leaders is straightforward: don't assume the manufacturing problem has already been solved simply because a technology has existed for decades.The field is still evolving, and some knowledge cannot be shortcut.About Phillip RamseyPhillip Ramsey is Chief Technical Officer at Sangamo Therapeutics and brings more than 35 years of experience across biotechnology and pharmaceutical manufacturing, technical development, operations, quality, and advanced therapies.Connect with Phillip Ramsey:https://www.linkedin.com/in/phillip-ramsey-a2074711/Sangamo Therapeutics:https://www.sangamo.com/Connect With BioTalk UnzippedGregory Austin on LinkedIn:https://www.linkedin.com/in/gregoryaustin1/Dr. Chad Briscoe on LinkedIn:https://www.linkedin.com/in/chadbriscoe/BioTalk Unzipped:https://www.biotalkunzipped.com/BioTalk Unzipped unzips, unlocks, and uncovers the stories behind medical progress through conversations with scientists, executives, entrepreneurs, and innovators advancing biotechnology, pharmaceuticals, and medical technology.Recorded onsite at the AAPS National Biotechnology Conference in Boston.Special thanks to AAPS and Rebecca Stauffer for supporting the BioTalk Unzipped interview series.
The noise in women's fitness has never been louder—and if you're wondering who to trust, you're not alone. Every scroll seems to deliver a new expert, a new rule, or a new warning that contradicts the last one, leaving many women feeling more confused than confident. Let's cut through the hype to help you understand why these conflicting messages exist and how to evaluate them without getting pulled into the latest trend. You'll learn a practical way to separate evidence from opinion so you can make informed decisions that actually support your health, strength, and longevity. Instead of adding to the noise in women's fitness, this conversation gives you the clarity and confidence to focus on what truly matters If this episode made you flip your workout routine — share it!
Welcome back to the Jack Westin MCAT Podcast with Mike and Molly! Last episode we covered DNA and RNA structure. Now we put that knowledge to work and answer the question that follows naturally: how do scientists actually study DNA, and how does the MCAT test those techniques?This is the DNA techniques episode, and it connects back to nearly everything you have already learned including amino acids, protein structure, hemoglobin, gel electrophoresis, blotting and central dogma.
HEALTH NEWS Berberine Shows Beneficial Effects on Metabolic Health, Study Reports Cooperation beats selfishness more often than scientists thought Sleep Disorders Don't Just Exhaust You. New Research Shows They Change Your Brain Two Hours of Strength Training Weekly Linked to Lower Heart Attack Risk in Women, Study Finds Planetary Health Diet lowers cardiovascular risk in older women Berberine Shows Beneficial Effects on Metabolic Health, Study Reports Peking Union Medical College (China), July 24 2026 (Natural News) A review published in the journal Molecules has summarized evidence indicating that berberine, a compound found in several plants, may influence glucose and lipid metabolism. According to the review, berberine has been associated with improvements in metabolic health markers across multiple studies. The compound is a yellow alkaloid extracted from plants such as European barberry, goldenseal, goldthread, Oregon grape, and tree turmeric. The review cited evidence that berberine may reduce blood glucose levels and improve insulin sensitivity, according to clinical trials. A systematic review of seven randomized clinical trials from China published in Nutrients revealed that berberine consistently alters the composition of gut bacteria in patients taking the supplement, and the analysis examined data across conditions including Type 2 diabetes, high cholesterol, and colorectal adenoma. Lipid panel improvements, including lower total cholesterol and triglycerides, were also reported in the reviewed studies. Cooperation beats selfishness more often than scientists thought Hebrew University of Jerusalem & Rutgers University, July 20 2026 (Eureaklert) For decades, one of the most influential ideas in evolutionary biology has suggested that when individuals act purely in their own self-interest, cooperation should eventually collapse. But a new study by the Hebrew University of Jerusalem and Rutgers University demonstrates that evolution may be far more optimistic than previously believed. Their findings reveal that cooperation does not require close family ties, reputation, repeated favors, or rigid social structures. Instead, cooperation can flourish simply because individuals respond differently to different opponents. The research proposes a new solution to one of biology's oldest puzzles: how cooperation survives in a world shaped by natural selection. Using mathematical models, evolutionary simulations, and populations of artificial intelligence agents, the researchers found that cooperation consistently evolved when individuals adjusted their willingness to cooperate according to whom they encountered. Rather than treating everyone identically, simple opponent-specific responses created stable communities in which cooperative behavior repeatedly outperformed purely selfish strategies. Perhaps the study's most surprising finding is that cooperative societies are not fragile exceptions. Across thousands of simulations, populations repeatedly evolved toward highly cooperative states, while purely selfish populations often failed to dominate. Even when mutations introduced new defectors, cooperative communities remained remarkably resilient. Sleep Disorders Don't Just Exhaust You. New Research Shows They Change Your Brain Florida International University, July 26, 2026 (SciTech Daily) A poor night's sleep can affect far more than energy the next day. Research from Florida International University links sleep disorders with structural differences in brain regions that help control attention, motivation and decision-making. Published in the journal Scientific Reports, the findings provide one of the broadest comparisons yet of how different sleep disorders are associated with the brain. The researchers compared two broad categories. Dyssomnias, such as insomnia and sleep apnea, interfere with falling asleep or remaining asleep. Parasomnias, including sleepwalking, nightmare disorder and sleep terrors, involve unusual events that disrupt the sleep cycle. Both categories were associated with decreases in the thalamus, a region that filters incoming information, supports concentration, and contributes to higher-level thinking. The researchers identified changes specifically in the pulvinar, an area within the thalamus that directs attention and helps manage cognitive control. These differences were connected with wider brain networks that support concentration and task performance. That pattern may help explain why disrupted sleep is associated with slower reactions, poorer decision-making and a greater likelihood of errors and accidents. Two Hours of Strength Training Weekly Linked to Lower Heart Attack Risk in Women, Study Finds Harvard School of Public Health, July 26 2026 (Natural News) A large-scale study published in the Journal of the American College of Cardiology has found that women who engage in regular strength training have a significantly lower risk of developing cardiovascular disease. The study examined data from 117,025 women over an average follow-up period of 14.5 years. Women who performed any amount of resistance training had a lower risk of cardiovascular events compared with those who did none. The association persisted after adjusting for overall lifestyle and health factors, the study stated. Among the study's specific findings, women who performed at least two hours of resistance training per week had a 44% lower risk of heart attack relative to women who did no resistance training, the report said. Any cardiovascular disease risk was 20% lower for that group, with an additional 5% reduction per extra hour of weekly resistance training, according to the study. The benefits of strength training were more pronounced among women who maintained resistance training consistently and trained both upper and lower body, according to the study. Adding strength training to regular aerobic exercise – such as walking or running – was linked to better heart health. Planetary Health Diet lowers cardiovascular risk in older women University of Caliornia at Irvine, July 25 2026 (News-Medical) A 20-year study of more than 65,000 postmenopausal women found that higher adherence to the Planetary Health Diet was associated with a lower risk of overall cardiovascular disease, coronary heart disease, stroke and heart failure. The findings showed that women whose diet most closely followed the Planetary Health Diet had about a 28% lower risk of cardiovascular disease compared with women in the group scoring the lowest for adherence. However, even moderate adherence to the diet was linked with lower risk. The Planetary Health Diet emphasizes foods such as fruits, vegetables, whole grains, legumes, nuts and unsaturated fats while limiting foods such as red and processed meats, added sugars, refined grains and saturated fats. The investigators followed 66,892 participants in the Women's Health Initiative (WHI). Overall, the results showed that women in the group whose diets were more closely aligned with the Planetary Health Diet had the lowest risk of cardiovascular disease. These women also showed a decreased risk of heart disease, heart failure and stroke risk compared to the women in the lowest-adherence group. However, even moderate adherence to the diet was associated with a decrease in risk, with each 10-point increase in Planetary Health Diet Index score linked to further risk reduction.
Why can two people with similar LDL levels experience radically different cardiovascular outcomes? In this episode, I speak with Peter Anderson about the possibility that endothelial nitric oxide may be one of the major variables separating these outcomes.We explore whether nitric oxide can be understood as a protective “bank” that is progressively depleted by ageing, hypertension, smoking, insulin resistance, obesity, sleep deprivation, psychological stress and circadian disruption.We also discuss dietary nitrate, rocket and beetroot, oral bacteria, sunlight, ultraviolet A, infrared light, movement, erectile function, flow-mediated dilation, ketosis, statins, calcium scores and the emerging controversy surrounding coronary CT analysis in lean-mass hyper-responders.CONSULT DR MAX
This week's topics include GLP1s and AUD, impact of CVD risk calculation, meeting lipid lowering targets, and no luck with a vaccine for gonorrhea.
Forever Young Radio Show with America's Natural Doctor Podcast
A breakthrough in inflammatory support has arrived in the natural health market. PEA, which stands for palmitoylethanolamide, is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods. Several human studies have demonstrated that PEA has broad- spectrum pain-relieving properties, anti-inflammatory effects, and nerve protection.To help us unpack all the research and studies we have Dr. Stengler joining us today.In addition to authoring 30 books on health and several best-sellers such as “The Natural Physician's Healing Therapies,” “Prescription for Natural Cures,” “Prescription for Drug Alternatives,” and “Outside the Box Cancer Therapies,” Dr. Stengler has been published in several peer-reviewed medical journals such as The International Journal of Family & Community Medicine, Endocrinology & Metabolism International Journal, and Journal of Nutritional Health & Food Engineering.Dr. Stengler's, NMD. The newest book is called, The Holistic Guide to Gut Health. A comprehensive yet accessible approach to healing leaky gut and the many uncomfortable symptoms it causes. Dr Stengler is also the founder of The Stengler Center for Integrative Medicine.Talking Points:Palmitoylethanolamide (PEA), is a naturally occurring fatty acid derivative made in the body and found in small amounts in foods.PEA was first discovered in 1957 by scientists at Merck Sharp & Dohme, who isolated it from egg yolk, peanut meal, and soy lecithin. They found that PEA had anti-inflammatory properties in guinea pigs.However, PEA's role as a potential therapeutic agent was not widely recognized until 1993, when Rita Levi-Montalcini and her colleagues published research that suggested PEA has anti-inflammatory properties. Levi-Montalcini's group termed PEA an autocoid local injury antagonist (ALIA), and suggested that it acts locally to counteract injury.Multiple studies have demonstrated that PEA improves all sorts of pain. For example, a 2023 analysis of 11 studies found that PEA improved pain of various conditions, including muscle and joints, nerves, gynecological, and digestive. In terms of joint pain, a high-quality study demonstrated that PEA significantly reduced adult joint pain compared to placebo. Moreover, 8 clinical trials demonstrated that PEA was effective for low back pain, sciatica, and carpal tunnel syndrome. Even migraine headache pain was shown in published research to be improved with PEA.Lipid mediators help to balance the immune, nervous, and endocrine systems, affecting pain pathways related to inflammation. But unfortunately, due to changing diets, many of us do not get the nutrition and activity we need to make enough PEA ourselves.Supplemental PEA, by Levagen+ is properly formulated for optimal bioavailability, 75% more bioavailable to cell receptors than dietary forms. Levagen+ liposomal delivery of PEA has been clinically studied and shows benefits in joint pain, nerve pain, migraine, infections, sleep, and cognitive function.Learn more about Emerald Labs PEA+ Levagen Use the code: Forever and get 20% off your order.
BUFFALO, NY — July 16, 2026 — A new #research paper was #published in Volume 18 of Aging on July 1, 2026, titled “Senescent cells accumulate lipid droplets.” The study was led by first author Noa Rachmian-Cooper and corresponding author Valery Krizhanovsky from the Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. Cellular senescence is a natural biological process in which damaged or stressed cells permanently stop dividing while remaining metabolically active. Although senescence helps suppress tumor formation and supports normal processes such as tissue repair and development, senescent cells accumulate with age and contribute to chronic inflammation and numerous age-related diseases, including cancer, cardiovascular disease, and Alzheimer's disease. While many of the biological effects of senescent cells have been linked to inflammatory signaling, much less has been understood about the metabolic changes that accompany senescence. In this study, the researchers investigated how cellular metabolism changes during senescence, with a particular focus on lipid metabolism. Using comprehensive metabolic profiling of human fibroblasts, they discovered that senescent cells accumulate high levels of triacylglycerols—the major precursors of lipid droplets—alongside increased glycolytic activity. Additional laboratory experiments confirmed that senescent cells contain significantly more lipid droplets than actively dividing cells. Full press release - https://www.aging-us.com/news-room/senescent-cells-found-to-accumulate-lipid-droplets-across-aging-and-alzheimers-disease DOI - https://doi.org/10.18632/aging.206390 Corresponding author - Valery Krizhanovsky - valery.krizhanovsky@weizmann.ac.il Abstract video - https://www.youtube.com/watch?v=GZbhY3wtGGI Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206390 Keywords - aging, senescence, lipid droplets, metabolism, Alzheimer's disease To learn more about the journal, please visit https://www.Aging-US.com and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
In this Season 6 Bonus Q&A I'm tackling the following questions from listeners:Why are my lipids suddenly so off? I never had issues when I was younger now every time I get my labs done they seem to be high. I'm a 49 year old woman.No matter what I do I can't seem to feel my glutes much when I train. Any tips? And what are your favorite exercises for building the glutes?I've noticed since my 40s that I get really tapped out when I'm around groups of people. Especially large groups. Even sometimes my coworkers chewing, coughing, making normal people noises drives me insane. To the point I've had to walk out of the room. What going on with me?I go to the bathroom 2 maybe 3x times a week. When I go it's normal but on the days I don't go I don't even have the urge to go. I've tried magnesium, kiwi, greens powders and probiotics nothing works.What's the difference between GERD and heartburn and acid reflux? I have a lot of upper GI tightness and burping.What do you eat?How many times a day do you eat? Do you ever have cheat meals?Enjoy this season 6 bonus!Join me on Instagram! My coaching is for women who are ready to stop chasing quick fixes and start building a body that actually responds through smarter nutrition, strength-focused training, functional health insight, and a more sustainable strategy. You can learn more and apply for coaching at revivewellness.health.Not ready to invest full in coaching? Book a Clarity Consultation!Try Syntrax! To try to the most delicious, gluten free, lactose free "top of the line" whey isolate AND save 15% follow this link. Discount automatically provided at checkout!Want some FREE LMNT? Use this link for a FREE sample pack with any order!Save 10% on...
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPW865. CME credit will be available until July 17, 2027.Combining Our Efforts for Patients With High-Risk ASCVD: Applying New Guidelines to Address the Challenge of Lipid Management In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.Disclosure information is available at the beginning of the video presentation.
What if the word uncurable really just means a doctor has run out of ideas? This episode dares you to question that verdict and discover a functional medicine approach built on gut health, trace minerals, and nervous system repair that has helped many people defy impossible odds and rewrite a hopeless diagnosis into a story of hope.Host Jenn Trepeck welcomes Dr. Aaron Hartman to Salad with a Side of Fries, where he shares how chronic illness recovery starts with the basics everyone overlooks, and why patients in remission from conditions like multiple sclerosis prove healing is possible even when doctors say there is nothing more they can do.What You Will Learn in This Episode:✅ Why the label “incurable” often just means idiopathic (unknown cause) and how functional medicine looks deeper✅ How gut health, sleep, and stress form the foundation of true chronic illness recovery✅ The connection between hypermobility, dysautonomia, mast cell activation, and autoimmune disease✅ Why organ meats, bone broth, and trace minerals support the nervous system and healingThe Salad With a Side of Fries podcast, hosted by Jenn Trepeck, explores real-life wellness and weight-loss topics, debunking myths, misinformation, and flawed science surrounding nutrition and the food industry. Let's dive into real-life wellness and weight loss, including drinking, eating out, and skipping the grocery store.TIMESTAMPS:00:00 Introduction to this episode on functional medicine and rethinking an incurable diagnosis03:47 Dr. Aaron Hartman explains cerebral palsy and his daughter Anna's dire early diagnosis07:17 Why incurable and idiopathic are labels Dr. Hartman refuses to accept and exploring the mast cell activation, hypermobility, autoimmune, gut, and dysautonomia super syndrome15:28 The big three foundations of gut health, stress regulation, and quality sleep for healing21:41 Why trace minerals, organ meats, and bone broth matter for true nutrient-dense nutrition24:38 Practical sleep hygiene tips rooted in circadian rhythm and nervous system regulation28:58 Balancing sugar addiction and dopamine-driven cravings with real food healing habits31:43 How the body's self-healing capacity applies at any age, from childhood through adulthood37:12 Lipid medicine: Using fats to heal your bodyKEY TAKEAWAYS:
Send us Fan MailFerroptosis, an iron-dependent cell death pathway driven by lipid peroxidation; chronoferoptosis, in which chronic stress sensitizes neurons gradually.TOPICS DISCUSSED:Cell Death Pathways: Apoptosis proceeds through regulated steps with surface “eat me” signals that enable non-inflammatory clearance by phagocytes, whereas ferroptosis and related pathways release cellular contents that can amplify local damage and inflammation.Ferroptosis Discovery: Work on glutamate toxicity in neuronal cell lines first identified a glutathione-depletion pathway termed oxytosis; parallel studies in cancer cells renamed and generalized it as ferroptosis to highlight iron's catalytic role.Lipid Peroxidation: Polyunsaturated fatty acids in membranes are oxidized non-enzymatically when ferrous iron reacts with hydrogen peroxide in the Fenton reaction, generating hydroxyl radicals that produce toxic lipid peroxides and reactive carbonyls that modify proteins.GPX4 & Glutathione: Glutathione peroxidase-4 is an enzyme that reduces lipid peroxides within membranes and requires glutathione as cofactor; depletion of either component removes this critical line of defense.Chronoferoptosis: Nine-day treatment of differentiated neuronal cells with chronic iron or glutathione synthesis inhibitor reduced GPX4 protein, raised basal lipid peroxidation, and increased cell death after addition of otherwise sublethal secondary stressors.Protective Compounds: Screening identified flavonoids such as fisetin and sterubin plus synthetic molecules J-147 and CMS-121 that block lipid peroxidation directly or indirectly and, in several cases, also raise glutathione levels.Human Disease Evidence: Postmortem brain tissue from Alzheimer's and Parkinson's patients shows elevated lipid peroxidation markers and altered iron handling in vulnerable regions; similar changes appear in animal models of multiple diseases.Dietary & NRF2 Links: Compounds that activate the NRF2 transcription factor, including sulforaphane from broccoli and certain flavonoids, upregulate antioxidant enzymes including GPX4 and may support long-term cellular resilience.ABOUT THE GUEST: Pamela Maher, PhD is a research professor at the Salk Institute for Biological Studies in La Jolla, California. Her laboratory studies ferroptosis mechanisms in neurodegenerative diseases and works to identify compounds that inhibit iron-dependent lipid peroxidation. Support the showSupport my work:Good Chemistry: Personalized, science-based health consulting. Work with Dr. Nick Jikomes directly.Affiliate Partners: Visit this link to see my affiliate partners and get discounts codes for products & services to support health.For all the ways you can support my efforts.
Broadcast from KSQD, Santa Cruz on 7-02-2026: Dr. Dawn devotes the first half of the show to a nuanced defense of GLP-1 receptor agonists, arguing the polarized debate treats obesity as a moral failure rather than a physiological one. She recounts the "Marilyn Monroe dress" moment that transformed semaglutide from diabetes drug into elite cosmetic tool, and pushes back on the puritanical framing that behavior change must be earned rather than pharmacologically enabled—noting we don't apply this logic to antihypertensives or statins. Dr. Dawn catalogs visceral fat as a genuine endocrine organ producing over 17 hormones, most of which drive self-perpetuating growth: leptin (this satiety hormone at high levels disables it's own brain receptor), IL-6, TNF-alpha (blocks insulin), resistin (increases insulin resistance and inflammation), PAI-2 (blocks clot breakdown, raising cardiovascular risk), retinol-binding protein 4 (impairs muscle glucose uptake), chemerin (recruits macrophages and directs fat to the belly), and visfatin. Only adiponectin declines with rising visceral fat. It improves insulin sensitivity, suppresses hepatic gluconeogenesis, and blocks IL-6 . Dr. Dawn describes GLP-1's neurobiological action: receptors in the hypothalamus, brainstem, hippocampus, and mesolimbic reward system, with the drugs quieting the brain's salience network so food loses its intrusive pull. Taste buds shift, sweet and salty become muted, and reward circuits stop firing on cheat foods—creating a window during which behavioral change becomes possible. Dr. Dawn frames group support through self-determination theory (autonomy, competence, relatedness), arguing GLP-1s create the cognitive bandwidth for behavioral programs to succeed. A Tufts study of patients discontinuing after 10% weight loss found those enrolled in behavioral support programs regained about three times less weight than usual-care controls, outperforming even medically-tailored meal plans. Group engagement doubled the time patients stayed on the medication. A November 2025 Nature study piggybacked on deep brain stimulation research at Penn. Electrodes implanted in the nucleus accumbens of post-bariatric patients recorded low-frequency brain activity surges during food-noise episodes on drug free patients. A third participant who started tirzepatide showed complete silencing of that signature—the first direct electrical confirmation that GLP-1s suppresses compulsive food thoughts in the reward center. RNA sequencing of adipose tissue from 25 obese patients before and after bariatric surgery, compared to 24 lean controls, revealed persistent epigenetic changes even after weight loss. Lipid-associated inflammatory macrophages drop but retain some of their pro-inflammatory epigenetics, explaining the well-known slippery slope back to obesity—and why Dr. Dawn suggests GLP-1s may work best as intermittent tools when behavioral maintenance starts slipping. An emailer asks about long-term smoking versus vaping data. Dr. Dawn notes there is no long-term data yet, but short-term evidence shows e-cigarettes contain nicotine, propylene glycol, reactive oxygen species, and nitrosamines, producing spirometry readings similar to mild COPD in otherwise-healthy vapers. Vaping over a year raises stroke relative risk by 1.62 and nearly doubles MI risk, and combining smoking and vaping produces a multiplicative rather than additive harm. Data on cancer will take decades to emerge. Researchers built a functioning underwater breathing apparatus for cockroaches with electrodes attached to brain and sensory organs allowing remote-controlled direction while preserving natural obstacle-navigation autonomy. The 10mm × 10mm sponge-based oxygen tank uses magnesium dioxide catalyzing hydrogen peroxide breakdown, delivering oxygen through silicone tubes to the roach's spiracles for up to three hours underwater. Deployemenet will improve search-and-rescue in flooded and collapsed structures where dogs cannot reach. A Science Advances paper from Yong Lin Kong's lab at Rice University describes 3D-printing electronic circuits directly onto living tissue. Researchers achieved microwave-focused annealing at sub-200-micrometer resolution. By selectively heating only conductive ink particles (copper, silver, gold) without damaging surrounding tissue, the technique enables printing circuits onto 3D-printed heart valves, tracheas, and ear scaffolds, potentially creating combined graft-and-sensor implants, ingestible diagnostic devices, and perhaps even decorative electronic tattoos. A single-shot reformulation of zanamivir (originally the inhaled flu drug Relenza) provided 76.1% flu protection in a 5,000-participant trial—far exceeding the roughly 40-45% offered by annual flu vaccines. Because zanamivir targets neuraminidase in a way that inactivates it if the virus tries to mutate around the drug, trapping newly-made viral copies inside their host cells, this approach works across all flu strains and could bypass the annual guessing game of trivalent vaccine formulation.
Send us Fan MailNearly a decade after the last major cholesterol guidelines were released, the new 2026 Multi-Specialty Lipid Guidelines introduce significant changes in how cardiovascular risk is assessed and managed. In this episode, Albert Lopez, DO, FACP, FASPC, explains why LDL cholesterol treatment goals have returned, how newer markers such as ApoB and Lipoprotein(a) are reshaping risk assessment, and why earlier, more aggressive treatment may help reduce the world's leading cause of death, cardiovascular disease.Dr. Al Lopez, DO, discusses the role of statins, non-HDL cholesterol, triglycerides, genetic cholesterol disorders, screening recommendations for children and older adults, and the importance of a team-based approach to prevention. Whether you're a healthcare professional or someone interested in protecting your heart health, this episode provides a practical overview of the latest evidence-based recommendations for preventing heart disease.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!
The Elective Rotation: A Critical Care Hospital Pharmacy Podcast
Show notes at pharmacyjoe.com/episode1139 In this episode, I'll discuss the dosing of lipid rescue therapy for LAST vs enteral drug toxicity.
In Part 2 of this special two-part series on genetic lipid disorders, Susan Robbins welcomes back renowned lipidologist Dr. Tom Dayspring for an eye-opening discussion on Lipoprotein(a), often written as Lp(a), one of the most common yet overlooked genetic cardiovascular risk factors in the world. While many people focus on standard cholesterol numbers, Dr. Dayspring explains why Lp(a) deserves far more attention and why major cardiovascular organizations now recommend that every person be tested at least once in their lifetime.Together, Susan and Dr. Dayspring break down the science behind Lp(a), how it differs from traditional cholesterol markers, and why elevated levels can significantly increase the risk of atherosclerosis, stroke, and aortic valve disease. They discuss the role genetics play in determining Lp(a) levels, why lifestyle changes remain important even when they do not directly lower Lp(a), and how advanced testing can provide a more complete picture of cardiovascular risk.This conversation also tackles common misconceptions surrounding cholesterol, statins, and influencer-driven health advice. Dr. Dayspring shares practical guidance on what to do if you discover you have elevated Lp(a), how to advocate for yourself within the healthcare system, and why understanding your unique biology is essential for protecting long-term health.In this episode:What Lipoprotein(a) or Lp(a) is and why it mattersWhy Lp(a) is one of the most common genetic lipid disorders worldwideThe connection between elevated Lp(a), heart disease, stroke, and aortic valve diseaseWhy every person should consider being tested for Lp(a) at least onceHow genetics determine Lp(a) levels throughout lifeThe difference between Lp(a), LDL cholesterol, and ApoBWhy standard cholesterol testing may miss important cardiovascular risk factorsThe role of oxidized phospholipids in cardiovascular diseaseIf you've ever been told your cholesterol is "normal" but still have a family history of heart disease, stroke, or unexplained cardiovascular events, this episode offers critical information that could help you ask better questions, pursue the right testing, and become a stronger advocate for your own health.Learn more about Dr. Tom Dayspring on the website shownotes!https://healthyawakening.co/2026/06/15/episode128/RESOURCES:Connect with Dr. Tom DayspringX: https://x.com/drlipidhttps://familyheart.org/https://healthyawakening.co/2026/06/15/episode128/Connect with Susan: https://healthyawakening.co/Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast
Dr. Hoffman continues his conversation with Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics.
Dr. Garth Nicolson, Founder, President, Chief Scientific Officer, and Emeritus Research Professor of Molecular Pathology at the Institute for Molecular Medicine in Huntington Beach, California, and Research Advisor for Nutritional Therapeutics, explains how membrane damage from free radicals and loss of mitochondrial transmembrane potential contribute to declining energy with age, noting studies in older adults showing improved energy output, fatigue, cognition, mood, and activity after NTFactor lipids, a protected phospholipid supplement balanced toward mitochondrial lipid composition. He describes evidence of lipid delivery using fluorescent-tagged lipids in sperm, with improved motility, and discusses applications including wound healing in veterans, removal of hydrophobic toxins via a concentration-driven “conveyor belt” process, and improved transport of nutrients like CoQ10. He details articles on normal aging, menopause-related changes supported by membranes, dementia risk linked to hearing loss, and rat studies showing delayed hearing loss with NTFactor, and mentions research on EMF sensitivity and planned schizophrenia trials.
Dr. Paulo Porto de Melo é uma autoridade máxima e brutal quando o assunto é a máquina mais complexa do universo. Ex-major do Exército por 19 anos e pioneiro na introdução da neurocirurgia robótica no Brasil , ele carrega o privilégio de ter tocado e operado mais de 10.000 cérebros humanos. Neste episódio, ele deixa a linguagem corporativa morna de lado para escancarar os segredos de bastidores que determinam quem terá uma mente brilhante ou quem sofrerá um colapso cognitivo total nas próximas décadas. Prepare-se para descobrir a verdade oculta sobre a demência que começa a destruir seus neurônios 20 anos antes do primeiro sintoma aparecer. Dr. Paulo revela o perigo invisível por trás dos remédios para dormir , o impacto destrutivo da cafeína no cérebro , a farsa do açúcar que causa o "Diabetes Tipo 3" , e uma descoberta científica chocante: a comunicação quântica dos neurônios através de fótons de luz. Uma verdadeira aula de sobrevivência e alta performance biológica que vai redefinir o seu futuro.Patrocinador:Clinica RUV - Harmonização que respeita quem você é.https://www.instagram.com/dra.najlavicentini/Disponivel Também no Youtube:https://youtu.be/cOwuA8H2SLc00:00:00 - O perigo ético da Neuralink e os backdoors chips cerebrais. 00:05:30 - Como prevenir 45% das demências e blindar sua coluna contra hérnias. 00:08:20 - Diabetes Tipo 3: A falência energética e a fome celular dos neurônios. 00:14:00 - O chocante Estudo das Freiras: Caminhos alternativos e redundância cognitiva. 00:18:10 - Lipidômica: O teste definitivo da ponta do dedo para equilibrar sua membrana celular. 00:23:50 - O erro do prato brasileiro: A ordem que você come altera sua glicose em 70%. 00:25:20 - Jejun intermitente, autofagia e o sinal de qualidade para o corpo. 00:34:00 - A verdadeira arquitetura do sono e a redução de 60% dos neurônios. 00:36:10 - Por que os remédios para dormir são uma farsa que te deixa cansado. 00:41:30 - Cafeína e o receptor de Adenosina: O soco no queixo da sua energia. 00:47:40 - O erro fatal de tomar café imediatamente após acordar. 00:53:00 - O piano genético e como a atividade física afasta doenças crônicas. 01:00:00 - Cortisol, privação de sono militar e a técnica limite da CIA. 01:13:30 - Cérebro Quântico: A descoberta dos fótons de luz entre neurônios. 01:17:20 - O caso real do tumor que era um abscesso: O diagnóstico pelo cheiro. 01:20:00 - AVC Isquêmico vs Hemorrágico e os sinais de alerta definitivos. 01:52:00 - Como os restaurantes usam a neurociência e luzes amarelas para hackear sua fome. Siga a Dr. Paulo no Instagram:https://www.instagram.com/ppmelo/Nos Siga:Marcelo Toledo: https://www.instagram.com/marcelotoledoInstagram: https://www.instagram.com/excepcionaispodcastTikTok: https://www.tiktok.com/@excepcionaispodcast
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Tom Dayspring is a world-renowned lipidologist and one of the most thoughtful teachers in the field of lipid metabolism. In this episode, Tom returns to The Drive for a deep dive into the relationship between lipids and brain health, beginning with the fundamentals of cholesterol transport before exploring why the brain's cholesterol system operates almost entirely independently from the rest of the body. Tom examines the roles of apoB, apoA-I, and especially apoE in cholesterol homeostasis, discusses how APOE genotype influences Alzheimer's disease risk, and unpacks the complex links between cholesterol metabolism, amyloid, and tau pathology. He also reviews what is currently known—and still uncertain—about the effects of statins, ezetimibe, omega-3 fatty acids, and emerging CETP inhibitors on brain health and neurodegenerative disease risk. Although highly technical, this conversation provides an essential framework for understanding the nuanced relationship between lipid-lowering therapies, cardiovascular disease prevention, and neurodegenerative diseases in an area often clouded by misinformation. We discuss: The fundamentals of cholesterol transport in the body, and how peripheral cholesterol metabolism differs from cholesterol handling in the brain [2:45]; How cholesterol is transported through plasma and stored within cells, and why lowering LDL cholesterol does not deplete the body or brain of cholesterol [11:45]; How apoB particles drive atherosclerosis, why lowering lipids matters, and the factors that influence individual cardiovascular risk [20:00]; How the brain produces and transports its own cholesterol using apoE lipoproteins independently of circulating cholesterol and apoB-containing lipoproteins [29:00]; How apoB structure influences LDL receptor binding and LDL clearance [39:00]; How neurons acquire cholesterol from apoE-containing lipoproteins and why desmosterol serves as a unique marker of cholesterol synthesis in the brain [41:45]; The difference between the APOE gene and the apoE protein, the major APOE genotypes found in humans, and how APOE4 influences Alzheimer's disease risk [48:45]; HDL function beyond cholesterol: immune function, protein cargo, and communication with the brain [53:30]; How APOE4-associated defects in brain cholesterol transport may promote Alzheimer's disease: amyloid production, neuronal cholesterol homeostasis, and cholesterol clearance [58:00]; Statins and brain health: reviewing the evidence of the potential impact of statins on cognition and Alzheimer's disease risk [1:09:00]; Desmosterol and 24S-hydroxycholesterol as biomarkers of brain cholesterol metabolism and statin effects [1:17:15]; Possible cognitive benefits of ezetimibe beyond lowering apoB [1:19:30]; EPA, DHA, and the evidence for omega-3 fatty acids in brain health [1:23:15]; Obicetrapib: an emerging CETP inhibitor with potential implications for both cardiovascular and brain health [1:31:00]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
In this episode of Everyday Epigenetics: Raw. Real. Relatable., Susan Robbins is joined by renowned expert lipidologist Dr. Tom Dayspring for Part 1 of a special two-part series on genetically driven lipid disorders. Together, they explore phytosterolemia (formerly known as sitosterolemia), a little-known but potentially serious genetic condition that affects how the body absorbs and processes plant sterols. While often overlooked in conventional healthcare, this disorder can contribute to elevated cholesterol markers, cardiovascular risk, xanthomas, kidney issues, and other health concerns when left undetected.Dr. Dayspring breaks down the complex science of cholesterol absorption, plant sterols, and the ABCG5 and ABCG8 genes in a way that is easy to understand. Susan shares what she has observed through years of genetic testing and coaching, including how frequently she is seeing these gene variants appear in practice and why many people are being missed by standard testing. This conversation highlights the importance of personalized medicine, advanced lipid testing, and understanding the unique ways genetics can influence long-term health outcomes.In this episode:What phytosterolemia is and why it is often missedThe difference between cholesterol and plant sterolsHow the ABCG5 and ABCG8 genes regulate sterol absorptionWhy some people absorb significantly more cholesterol than othersThe connection between plant sterol hyper-absorption and cardiovascular disease riskWhy standard cholesterol testing may miss important cluesThe role of sitosterol and campesterol testingHow phytosterols can impact cell membranes, kidneys, joints, blood cells, and other tissuesThe difference between heterozygous and homozygous loss-of-function gene variantsWhy many patients are told their cholesterol is "fine" when deeper issues may existThe importance of ApoB, non-HDL cholesterol, and advanced lipid testingWhy some cholesterol-lowering therapies work better than others depending on geneticsHow lifestyle, nutrition, and personalized interventions can support lipid healthWhen to consider working with a lipid specialistIf you have a family history of heart disease, unexplained cholesterol elevations, or have been told your numbers are "normal" despite ongoing concerns, or if use of statins hasn't helped yu, this episode offers valuable insight into a genetic factor that is rarely discussed but can have a significant impact on long-term health.Learn more about Dr. Tom Dayspring on the website shownotes!https://healthyawakening.co/2026/06/08/episode127/RESOURCES:Connect with Dr. Tom DayspringX: https://x.com/drlipidhttps://healthyawakening.co/2026/06/08/episode127/Connect with Susan: https://healthyawakening.co/Visit the website: healthyawakening.co/podcastFind listening links here: https://healthyawakening.co/linksP.S. Want reminders about episodes? Sign up for our newsletter, you can find the link on our podcast page! https://healthyawakening.co/podcast
Welcome to this week's Midlife Minute. Today, I'm focusing on all the questions I received about gallbladder health, including HRT-provoking symptoms, supplements that improve gallbladder health, and evidence-based food interventions. IN THIS EPISODE, YOU WILL LEARN: Why the risk of gallstones and gallbladder inflammation increases during the menopause transition How estrogen and progesterone HRT have different effects on gallbladder functioning The differences in risk between transdermal and oral HRT How the progesterone in HRT can cause gallbladder issues in some women What TUDCA is, and how it supports gallbladder health The value of TUDCA for women who have had their gallbladders removed How various nutrients and supplements support bile flow and gallbladder health What can contribute to gallstone formation Connect with Cynthia Thurlow Follow on X, Instagram & LinkedIn Check out Cynthia's website. Submit your questions to support@cynthiathurlow.com Join other like-minded women in a supportive, nurturing community: The Midlife Pause/Cynthia Thurlow. Purchase Cynthia's book, The Menopause Gut. Cynthia's Intermittent Fasting Transformation Book The Midlife Pause Supplement Line Gallbladder Research: Cabrera D, Arab JP, Arrese M. UDCA, NorUDCA, and TUDCA in liver diseases: a review of their mechanisms of action and clinical applications. Seminars in Liver Disease. 2019;39(4):397–404. doi:10.1055/s-0039-1696799 Vang S, Longley K, Steer CJ, Low WC. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Global Advances in Health and Medicine. 2014;3(3):58–69. doi:10.7453/gahmj.2014.017 Bai M, Yang L, Liao H, et al. Tauroursodeoxycholic acid improves nonalcoholic fatty liver disease by regulating gut microbiota and bile acid metabolism. Journal of Agricultural and Food Chemistry. 2024;72(41):22655–22668. doi:10.1021/acs.jafc.4c04630 Simon JA, Hudes ES. Relation of serum ascorbic acid to serum vitamin B12, serum ferritin, and kidney stones in US adults. *Archives of Internal Medicine.*1999;159(6):619–624. doi:10.1001/archinte.159.6.619 Walcher T, Haenle MM, Kron M, et al. Vitamin C supplement use may protect against gallstones: an observational study on a randomly selected population. BMC Gastroenterology. 2009;9:74. doi:10.1186/1471-230X-9-74 Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Long-term intake of dietary fiber and decreased risk of cholecystectomy in women. American Journal of Gastroenterology. 2004;99(7):1364–1370. doi:10.1111/j.1572-0241.2004.30281.x Leitzmann MF, Stampfer MJ, Willett WC, Spiegelman D, Colditz GA, Giovannucci EL. Coffee intake is associated with lower risk of symptomatic gallstone disease in women. Gastroenterology. 2002;123(6):1823–1830. doi:10.1053/gast.2002.37085 Moerman CJ, Smeets FW, Kromhout D. Dietary risk factors for clinically diagnosed gallstones in middle-aged men — a 25-year follow-up study. Annals of Epidemiology. 1994;4(3):248–254. doi:10.1016/1047-2797(94)90099-x Association between dietary magnesium intake and gallstones: the mediating role of atherogenic index of plasma. Lipids in Health and Disease. 2024;23(1):82. doi:10.1186/s12944-024-02074-4 Pitt HA, Doty JE, Murphy MM, Schwarz MB. Progesterone alters biliary flow dynamics. Annals of Surgery. 1999;229(2):205–209. doi:10.1097/00000658-199902000-00008
Join us as we review recent articles and news featured in The DIGEST, including updated lipid guidelines, GLP1 agonists holds and procedures, the newest drug in pancreatic cancer, and discontinuing thyroid supplementation. Fill your brain hole with a delicious stack of hotcakes! Featuring Drs. Nora Taranto (@norataranto), Laura Glick (@lauraglick) and Matt Watto (@doctorwatto).Claim free CME for this episode at curbsiders.vcuhealth.org!Episodes | Subscribe | Spotify | Swag! |Mailing List | Contact | CME!Credits Written and Hosted by: Nora Taranto MD MSCE, Laura Glick MD, Matthew Watto MD, FACP Cover Art: Nora Taranto MD MSCE Reviewers: Emi Okamoto MD Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro and pun Lipid Management Guidelines Overview Emerging Treatments in Oncology Press Release on a new KRAS Inhibitor for Pancreatic Cancer Perioperative Considerations for GLP-1 Use Deprescribing Levothyroxine in Older Adults Sponsor: Panacea FinancialIf you're about to make the leap into residency and feeling the financial pressure of that transition, visit PanaceaFinancial.com/curbsiders today. Sponsor: UpToDatefor a limited time, get 10% off UpToDate packages with code CURB10. Visit store.uptodate.com to save on your annual or longer personal UpToDate subscription today.
© 2020-2026 Ivy Podcast Discovery LLC
